PDX Model Biomarker Quantification for Drug Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for estimating the efficacy of drugs or therapies in cancer treatment rely heavily on clinical trials, which are costly, time-consuming, and pose risks to patients due to the need for actual patient administration.
Innovation Solution
The method involves analyzing gene information from human diseased tissue to identify specific biomarkers, then using fluorescent nanoparticles like phosphor integrated dots to quantify the expression status of these biomarkers in laboratory animals transplanted with human tissue, thereby estimating therapeutic effects and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical trials are conducted to verify drug efficacy, then accurate therapeutic effect data is obtained, but patient safety risks and ethical concerns increase
Solution Approach 1:
The patent creates a copy of the human tumor microenvironment by transplanting patient-derived tumor tissue into immunodeficient mice, generating PDX models that replicate human cancer characteristics. This copying approach allows preclinical testing of drug efficacy and toxicity in a system that closely mimics human pathology without exposing patients to unnecessary risks, thereby resolving the contradiction between obtaining accurate efficacy data and protecting patient safety
Solution Approach 2:
The patent performs preliminary drug testing in PDX mouse models before conducting clinical trials in humans. By evaluating drug efficacy, optimal dosing, and potential toxicity in the preclinical PDX model stage, the system identifies promising candidates while filtering out ineffective or harmful drugs, thus preventing patient exposure to suboptimal therapies and reducing clinical trial failures
2Reliability
If patient-derived tumor tissue is transplanted into mice to create PDX models, then test reliability and reproducibility improve, but model production complexity and cost increase
Solution Approach 1:
The patent establishes a universal PDX model platform that can accommodate various types of human tumor tissues (solid tumors, liquid biopsies) and test multiple drug candidates within the same immunodeficient mouse strain framework. This multi-functional approach allows different tumor types to be studied using standardized protocols and common infrastructure, reducing overall system complexity despite the sophisticated nature of individual models
Solution Approach 2:
The patent introduces immunodeficient mice as an intermediary system that bridges human tumor biology and preclinical drug testing. These mice serve as a mediator by providing a living host environment that maintains human tumor characteristics while allowing pharmacological intervention and observation, thus simplifying the transition from human tissue to testable model without requiring direct human experimentation
3Ease of manufacture
If cultured cancer cells are used to create tumor-bearing mice, then model production is easier and faster, but individual differences among tumor models increase
Solution Approach 1:
The patent copies the original patient tumor architecture and cellular composition directly into the mouse model by transplanting fresh tumor tissue or minimally processed tumor cells, rather than using extensively cultured cell lines. This copying approach preserves the heterogeneity and biological fidelity of the original tumor while maintaining production feasibility, achieving a balance between ease of manufacture and model homogeneity
Solution Approach 2:
The patent performs preliminary steps to maintain tumor cell viability and characteristics during the transplantation process, including optimized tissue processing protocols and immediate implantation into immunodeficient hosts. By acting quickly and using standardized procedures, the system minimizes the time tumors spend in culture, thereby reducing drift and maintaining compositional stability while keeping the process efficient and reproducible
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate estimation of drug efficacy and side effects with high precision, reducing the need for clinical trials and minimizing risks to patients by simulating therapeutic outcomes in a controlled laboratory setting.
Implementation Method 1
using fluorescent nanoparticles like phosphor integrated dots to quantify the expression status of these biomarkers
Data Source
AI summary
Disclosed herein is a method including: acquiring one or more pieces of information including information about expression status of a specific biomarker in a lesion collected from a human by using a laboratory animal transplanted with the lesion; and using the information to estimate therapeutic efficacy through analysis.